Arsenic trioxide

Also known as: Arsenic Sesquioxide Arsenic Oxidearsenous Trioxide

Therapeutic indications

Arsenic trioxide is indicated for:

Population group: both men and women, only adults (18 years old or older)

Arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with:

Νewly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤10 × 10³/µl) in combination with all-trans-retinoic acid (ATRA)
Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.

For this indication, competent medicine agencies globally authorize below treatments (click for details):